Literature DB >> 28509207

Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid.

Tomokazu Matsuura1, Shu Wakino2, Ayumi Yoshifuji2, Toshifumi Nakamura2, Hirobumi Tokuyama2, Akinori Hashiguchi3, Konosuke Konishi2, Takeshi Iwasa4, Masaaki Shoji4, Ako Hosono5, Ken Ohashi4, Hirokazu Chuman6, Hiroshi Itoh2.   

Abstract

Long-term nephrotoxicity of ifosfamide is occasionally progressive, and, in such case, there has been no specific treatment to prevent progression. It has been reported that the presence of karyomegalic interstitial nephritis, which is rare type of interstitial nephritis, may be related to ifosfamide-induced nephropathy with poor prognosis and resistant to the immunosuppressive therapy. A 15-year-old boy presented with progressive nephrotoxicity 3 years after systemic chemotherapy with ifosfamide and cisplatin for the treatment of osteosarcoma. Renal biopsy revealed the severe tubulointerstitial nephritis with tubular atrophy and focal global and segmental glomerular sclerosis. It also showed tubular epithelial cells with variably sized nuclei, some of which were massively enlarged, abnormal hyperchromatic, irregular shaped, and bizarre-appearing. These morphological changes were suggestive of the histology of karyomegalic interstitial nephritis. Corticosteroid retarded the progression of nephrotoxicity. The present case is the first report, suggesting that corticosteroid was effective against the late-onset renal toxicity by ifosfamide therapy. Our case also suggests that karyomegalic interstitial nephritis may be the result of long-term nephrotoxicity of ifosfamide. Since concurrent treatment with cisplatin is one of the risk factors for ifosfamide nephrotoxicity, there is a possibility that cisplatin may have a synergetic effect with ifosfamide for producing karyomegalic interstitial nephritis.

Entities:  

Keywords:  Corticosteroid; Ifosfamide; Karyomegalic interstitial nephritis; Long-term nephrotoxicity; Tubulointerstitial nephritis

Year:  2014        PMID: 28509207      PMCID: PMC5413667          DOI: 10.1007/s13730-014-0124-3

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  17 in total

1.  Progressive glomerular toxicity of ifosfamide in children.

Authors:  V K Prasad; I J Lewis; S R Aparicio; D Heney; J P Hale; C C Bailey; S E Kinsey
Journal:  Med Pediatr Oncol       Date:  1996-09

Review 2.  Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Deborah P Jones; Sheri L Spunt; Daniel Green; James E Springate
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

3.  Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients.

Authors:  J S Berns; A Haghighat; A Staddon; R M Cohen; R Schmidt; S Fisher; M R Rudnick; J E Tomaszewski
Journal:  Cancer       Date:  1995-08-01       Impact factor: 6.860

4.  Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats.

Authors:  Ahmet Ateşşahín; Ali Osman Ceríbaşi; Abdurrauf Yuce; Ozgür Bulmus; Gürkan Cikim
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-02       Impact factor: 4.080

5.  Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.

Authors:  R Rossi; A Gödde; A Kleinebrand; M Riepenhausen; J Boos; J Ritter; H Jürgens
Journal:  J Clin Oncol       Date:  1994-01       Impact factor: 44.544

6.  Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.

Authors:  Roderick Skinner; Annie Parry; Lisa Price; Michael Cole; Alan W Craft; Andrew D J Pearson
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

7.  Karyomegalic interstitial nephritis: further support for a distinct entity and evidence for a genetic defect.

Authors:  M Spoendlin; H Moch; F Brunner; W Brunner; H R Burger; D Kiss; W Wegmann; P Dalquen; M Oberholzer; G Thiel
Journal:  Am J Kidney Dis       Date:  1995-02       Impact factor: 8.860

Review 8.  Ifosfamide nephrotoxicity in children: histopathological features in two cases.

Authors:  B J Morland; J R Mann; D V Milford; F Raafat; M C Stevens
Journal:  Med Pediatr Oncol       Date:  1996-07

9.  Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy.

Authors:  Tom McCulloch; Andrew Prayle; Andy Lunn; Alan R Watson
Journal:  Pediatr Nephrol       Date:  2011-03-18       Impact factor: 3.714

10.  Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.

Authors:  R Skinner; S J Cotterill; M C Stevens
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

View more
  3 in total

1.  Acute Tubulointerstitial Nephritis in Clinical Oncology: A Comprehensive Review.

Authors:  Laura Martínez-Valenzuela; Juliana Draibe; Xavier Fulladosa; Montserrat Gomà; Francisco Gómez; Paula Antón; Josep María Cruzado; Joan Torras
Journal:  Int J Mol Sci       Date:  2021-02-26       Impact factor: 5.923

2.  Ifosfamide-induced acute kidney injury in a patient with leiomyosarcoma: A case report.

Authors:  Javad Boskabadi; Ehsan Yousefi-Mazhin; Ebrahim Salehifar
Journal:  Cancer Rep (Hoboken)       Date:  2022-07-13

3.  Karyomegalic interstitial nephropathy following ifosfamide therapy.

Authors:  R Jayasurya; B H Srinivas; M Ponraj; S Haridasan; S Parameswaran; P S Priyamvada
Journal:  Indian J Nephrol       Date:  2016 Jul-Aug
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.